Wantstats
Company ProfilePremium

Mallinckrodt

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Mallinckrodt - Healthcare showcase

Year Founded & Workforce

1840

5,000 Employees

Industry

Healthcare

Services

Specialty Brands
M

Mallinckrodt Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Mallinckrodt Overview

Company Headquarter: US

Founded: 1840

Workforce: 1000 to 5000 Employees

Company Working:

Mallinckrodt is a specialty pharmaceuticals company which develops, manufactures, markets, and distributes specialty pharmaceutical drugs and therapies. The company focuses on underserved patients of neurology, rheumatology, nephrology, pulmonology, and ophthalmology. The company also focuses on immunotherapy, neonatal respiratory critical care therapies, analgesics, and gastrointestinal products.

Company Snapshot

$2,923M

Revenue

5,000

Employees

1840

Founded

SWOT Analysis

Strengths

  • Strong market presence
  • Vast product portfolio

Weaknesses

  • Company’s manufacturing facilities are limited to developed nations such as the US and the UK

Opportunities

  • Expanding in developing economies
  • Launching new products related to the market

Threats

  • Stringent government regulations
  • Growing market competition

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–ApprovalMallinckrodt received a supplement approval from USFDA for Amitiza (lubiprostone), used for the treatment of irritable bowel syndrome.
–AcquisitionMallinckrodt acquired Sukampo Pharmaceutical, a global biopharmaceutical company. With this, the company has expanded its specialty brands business.
–AcquisitionMallinckrodt acquired Cadence Pharmaceuticals. With this, the company has expanded its specialty generics business.

Product Offering

  • Mallinckrodt
    • Specialty Brands

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 2,923 Mn in 2015 to USD 3,222 Mn in 2017.
Mallinckrodt — By Business Segment
Series (USD Mn)201520162017
Sales2,9233,3813,222
R&D Expenditure204.6263.7277.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →